BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Armed with cutting-edge technology and MIT science, experienced business and medic...
Armed with cutting-edge technology and MIT scie...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
Cerecor is an integrated biopharmaceutical company developing innovative therapies...
Cerecor is an integrated biopharmaceutical comp...
Helius Medical Technologies, Inc. (Helius) is a neurotech company in the medical d...
Helius Medical Technologies, Inc. (Helius) is a...
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Join the National Investor Network and get the latest information with your interests in mind.